Data from randomized, double-blind study in 226 adults to be presented as an oral abstract May 26, 2026 07:00 ET…
Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in…
Study now open for enrollment at leading academic medical centersCARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity…
NEW WESTMINSTER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- A BC-led clinical research team is behind a study that…
May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed…
May 15, 2026 20:19 ET | Source: Regeneron Pharmaceuticals, Inc. The trial did not reach statistical significance for the primary…
GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech company pioneering a new treatment paradigm for acute…
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…